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Abstract
 
Natural killer (NK) cells can spontaneously lyse certain virally infected and transformed cells.
However, early in immune responses NK cells are further activated and recruited to tissue sites
where they perform effector functions. This process is dependent on cytokines, but it is unclear if
it is regulated by NK cell recognition of susceptible target cells. We show here that infiltration of
activated NK cells into the peritoneal cavity in response to tumor cells is controlled by the tumor
major histocompatibility complex (MHC) class I phenotype. Tumor cells lacking appropriate
MHC class I expression induced NK cell infiltration, cytotoxic activation, and induction of tran-
scription of interferon 
 
g
 
 in NK cells. The induction of these responses was inhibited by restora-
tion of tumor cell MHC class I expression. The NK cells responding to MHC class I–deficient
tumor cells were 
 
z
 
10 times as active as endogenous NK cells on a per cell basis. Although these
effector cells showed a typical NK specificity in that they preferentially killed MHC class I–defi-
cient cells, this specificity was even more distinct during induction of the intraperitoneal response.
Observations are discussed in relation to a possible adaptive component of the NK response, i.e.,
recruitment/activation in response to challenges that only NK cells are able to neutralize.
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Introduction
 
Natural killer cells are of the lymphoid lineage, although
they are distinct from T and B cells. They can rapidly reject
tumor cells and bone marrow transplants without prior
sensitization (1). The specificity of NK cells depend on an
interplay between germ line–encoded inhibitory receptors,
which are specific for MHC class I, and less characterized
activating receptors (2–4). Cells with defects in their MHC
class I expression are particularly susceptible to NK cell–
mediated lysis, as they fail to cancel the lytic program
through inhibitory receptors (2, 3, 5). NK cells can infil-
trate both murine and human malignancies, and they are
especially efficient in the rejection of tumors lacking host
MHC class I molecules, including those with defects in
transporter associated with antigen processing (TAP)
 
1
 
 or 
 
b
 
2
microglobulin
 
 
 
(
 
b
 
2
 
m) genes (6, 7).
In vivo NK cells can be recruited locally by inoculation
of tumor cells (8–13), treatment with biological response
modifiers (14, 15), and viral infection (16–18). NK cell mi-
gration can be induced by several chemokines such as mac-
rophage inflammatory protein 1
 
a
 
 and IFN-
 
g
 
–inducible
protein 10 (18–21), as well as TNF-
 
a
 
 (13, 15, 21) and IL-2
(22). Gene knockout mice deficient for certain of these cy-
tokines show considerable defects in the migration of NK
cells during local responses to tumors (13) and viruses (18).
In addition, NK cells are activated to become more cyto-
toxic and to produce IFN-
 
g
 
 during the early phases of in-
fections (16–18, 23, 24), and this may improve the chance
for survival of the host (25–27). The activation of NK cells
occurs in response to 
 
a
 
/
 
b
 
 IFNs or IL-12 (23, 24, 28). Al-
though NK cells may be activated during early immune re-
sponses by cytokines, they are typically regarded as an in-
nate immune mechanism. It is thus unclear whether they
can also be activated in response to abnormal cells with a
phenotype that they are particularly competent to fight.
Several previous studies have demonstrated infiltration of
NK cells in the peritoneal cavity upon inoculation of tu-
mor cells (12, 13), but the specificity in the induction of
 
Address correspondence to Rickard Glas, Microbiology and Tumor Biol-
ogy Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden.
Phone: 46-8-728-6981; Fax: 46-8-331-399; E-mail: rickard.glas@mtc.ki.se
 
1
 
Abbreviations used in this paper:
 
 DELFIA, dissociation-enhanced lanthanide
fluoroimmunoassays; FSC, forward scatter; PECs, peritoneal exudate cells;
SSC, side scatter; TAP, transporter associated with antigen processing. 
130
 
Regulation of NK Cell Activation and Migration by MHC Class I Molecules
 
this response is unclear. We set out to investigate this prob-
lem and particularly whether the induction was controlled
by tumor MHC class I molecules, as NK cells detect the
lack of MHC class I during the effector cell stage.
We found a low cytotoxic activity of resident intraperi-
toneal NK cells and a strong recruitment and activation of
host NK cells after inoculation of tumor cells, provided that
the tumor cells lacked critical host MHC class I molecules.
In contrast, tumors with full MHC class I expression in-
duced only weak responses in terms of both recruitment
and activation of NK cells. At least two different mecha-
nisms contributed to the response: an increase in NK cell
number and a strongly augmented cytotoxic capacity per
cell (compared with endogenous NK cells). The activated
NK cells preferentially killed MHC class I–deficient target
cells that had been used for activation, but the specificity
for MHC class I–deficient cells was even more distinct in
the activation step compared with the effector–target inter-
action. We also found that transcription of IFN-
 
g
 
 was in-
duced in NK cells by MHC class I–deficient tumor cells
but not by MHC class I transfectants. This NK activation
pathway may increase early host resistance by amplification
of the inflammatory response and bias the development of
Th cells.
 
Materials and Methods
 
Mice.
 
All mice, except for SCID mice (29), were bred at the
Department of Tumor Biology and at the Microbiology and Tu-
mor Biology Center, Karolinska Institute. B6 mice are of the
H-2
 
b
 
 haplotype, and A 
 
3
 
 CBA mice are an F1 cross between A/Sn
of the H-2
 
a
 
 and CBA of the H-2K
 
k
 
 haplotype, respectively.
 
Cell Lines.
 
RMA is a Rauscher’s virus–induced lymphoma cell
line derived from B6 (H-2
 
b
 
), and RMA-S is a TAP-2–defective
variant of RMA (30, 31). RMA-S.mtp2 (32) and RMA-S.Ham-2
(33) are rat and mouse TAP-2 transfectants of RMA-S, respec-
tively. YAC is a Moloney leukemia virus–induced lymphoma cell
line from A/Sn (H-2
 
a
 
), and AH-2
 
2
 
 is a 
 
b
 
2
 
m
 
2
 
 variant of YAC.
E49.3-
 
b
 
2
 
m is a 
 
b
 
2
 
m
 
1
 
 transfectant of AH-2
 
2
 
 (34).
 
Generation of In Vivo–activated NK Cells.
 
B6 or A 
 
3
 
 CBA mice
were inoculated intraperitoneally with 10
 
6
 
 or 10
 
7
 
 cells resuspended
in PBS, irradiated with 10,000 rads, or PBS alone. A 
 
3
 
 CBA F1
mice were used instead of parental A/Sn due to the low endoge-
nous NK activity present in A/Sn. The tumor cells were for most
experiments maintained as ascite cell lines in vivo but were also
grown in vitro (the cell lines derived from YAC, used for in vivo
injections, were always maintained as ascite lines). After 1–6 d, the
mice were killed, and 2–3 ml of RPMI was injected twice into
the intraperitoneal cavity to harvest peritoneal exudate cells
(PECs). The cells were washed and analyzed for cytotoxic activ-
ity in a standard 4–5-h 
 
51
 
Cr-release assay or tested for expression
of cell surface markers by FACS
 
®
 
.
 
mAbs, FACS
 
®
 
 Analysis, FACS
 
®
 
 Sorting, and Complement-medi-
ated Depletion of Effector Cell Populations.
 
For flow cytometry,
FITC- or PE-conjugated mAbs directed against various cell surface
antigens were used. These were directed against NK1.1 (PK136),
Ly49C (5E6), CD4 (L3T4), and CD8 (53-6.7). All conjugated
antibodies were purchased from PharMingen. Before FACS
 
®
 
analysis (on a FACScan™; Becton Dickinson), cells were incu-
 
bated with 0.5–1.0 
 
m
 
g of antibody for 30–60 min at 4
 
8
 
C. For in-
hibition of unspecific binding of fluoresceinated mAbs, the staining
buffer contained 30% FCS and 5% mouse serum in hybridoma
supernatant of 2G.4 specific for FcRII
 
g
 
 (HB197; American Type
Culture Collection). The analysis of 5E6 on NK1.1
 
1
 
 cells (see
Fig. 4) was gated on forward scatter (FSC)
 
low
 
 side scatter (SSC)
 
low
 
cells, due to high autofluorescence in FSC
 
high
 
SSC
 
high
 
 cells (Wright-
Giemsa stain suggested that these may correspond to macrophages).
NK1.1
 
1
 
 cells were always in the FSC
 
low
 
SSC
 
low
 
 population. To
generate pure NK1.1
 
1
 
 and NK1.1
 
2
 
 populations, PECs were la-
beled with anti-NK1.1 mAb according to the procedure above
and sorted on a FACScan™ (Becton Dickinson). For comple-
ment-mediated effector cell depletion, the cells were first incu-
bated with an antisera against asialo-GM
 
1 
 
or mAbs against CD4
or CD8 for 30 min and subsequently incubated with rabbit com-
plement diluted 1:8 for 75–90 min. These cells were subse-
quently used in a standard 
 
51
 
Cr-release assay.
 
Competitive PCR for Cytokine Transcripts.
 
Total RNA was ob-
tained from single-cell suspensions by using acid guanidium thio-
cyanate and phenol–chloroform extraction (35), based on the rapid
one-step procedure of Chomczynski and Sacchi (36). The aqueous
phase was collected, and the RNA was further purified and con-
centrated by precipitation with isopropanol and ethanol. 2 mg of
mRNA was denatured at 94
 
8
 
C for 5 min, reverse transcribed at
40°C for 45 min, and treated at 94°C for 5 min. The reverse tran-
scription was carried out in a total of 40 
 
m
 
l with 7.5 
 
m
 
M dithio-
threitol (GIBCO BRL), 0.5 mM nucleotides (dNTP; Pharmacia),
1 U/ml RNAsin (Promega Corp.), 5 mM random hexanucle-
otides (pd[N]6; Pharmacia), and 10 U/ml murine Moloney leuke-
mia virus reverse transcriptase (GIBCO BRL).
Each cDNA sample was amplified in a competitive PCR assay
(37). The PCR reaction was performed in 20 
 
m
 
l containing
0.2 mM dNTP, 25 mU/ml Taq polymerase (Perkin-Elmer Roche),
0.5 mM sense and antisense primers, cDNA, and 2 
 
m
 
l of compet-
itor fragments of different lengths but with the same primer bind-
ing sequences as the target DNA. The competitors for each cy-
tokine were diluted in a series of at least five threefold dilutions
for every sample. A negative control containing no template, a
competitor control, and cDNA controls were included in every
assay. Primer sequences, annealing temperatures, and competitors
for 
 
b
 
-actin, IFN-
 
g
 
, TNF-
 
a
 
, and IL-12 (p40) were the same as
previously reported (38–40). The PCR products were loaded on
a 2% agarose gel, electrophoresed, and photographed. The origi-
nal concentration of the competitor was known in all cases. The
concentrations of cDNA were calculated from cDNA and com-
petitor bands with equal intensity. The cytokine mRNA concen-
trations were expressed as percentages of the 
 
b
 
-actin mRNA
concentration for each sample.
 
Immunoassay for IFN-
 
a
 
, -
 
b
 
, and -
 
g
 
.
 
IFN-
 
a
 
 and -
 
b
 
 in serum was
measured separately in dissociation-enhanced lanthanide fluor-
oimmunoassays (DELFIA) as described (41). In brief, microtiter
plates were coated with sheep anti–IFN-
 
a
 
/
 
b 
 
and
 
 
 
incubated with
samples or standards and then with mAbs to IFN-
 
a
 
 or -
 
b
 
 labeled
with Europium lanthanide chelate. An enhancement solution was
added, and fluorescence was measured in a DELFIA fluorometer.
The values in Fig. 6 are displayed in international units, as deter-
mined by comparison with the signal generated by standard con-
centrations.
The secretion of IFN-
 
g
 
 protein was determined by Quantikine
ELISA (R & D Systems, Inc.). In brief, 2 
 
3
 
 10
 
6
 
 PECs were
plated in RPMI 1640 medium supplemented with 10% FCS in
flat-bottomed 96-well plates. Supernatants were harvested after
20 h. PECs were plated alone and in the presence of RMA-S 
131
 
Glas et al.
cells (2 
 
3
 
 10
 
5
 
 cells per well) or IL-12 (50 IU/ml). The Quanti-
kine ELISA is a sandwich ELISA, and the signal was quantified as
compared with an IFN-
 
g
 
 standard.
 
Results
 
Induction of a Cytotoxic NK Cell Response by MHC Class
I–deficient Lymphoma Cells.
 
To monitor the activity and
specificity of NK cells during tumor cell rejection, we in-
oculated TAP-2–deficient mutant RMA-S cells intraperi-
toneally into syngeneic B6 mice. The mice were given irra-
diated tumor cells and killed 1–6 d after inoculation. PECs
were obtained and tested for cytotoxicity against a panel of
target cells. We found that PECs from RMA-S–inoculated
B6 mice were highly cytotoxic against RMA-S (not shown)
as well as YAC-1 cells (Fig. 1 b), whereas the cytotoxic
activity from BSS-injected control mice was low (Fig. 1
b). The cytotoxic activity induced by RMA-S was detected
after only 2 d, peaked by 3 d after inoculation (Fig. 1 a),
and was local; it could not be observed among spleen cells
(Fig. 1 b). The cytotoxicity was mediated by NK cells, as
pretreatment of the effector cell population with anti-CD4
or anti-CD8 antibodies plus complement had no effect,
whereas antiasialo-GM
 
1
 
 plus complement depleted the ac-
tivity (Fig. 1 c and data not shown). These data are in line
with several previous studies showing migration of NK cells
in response to tumor cells in the lung, liver, and peritoneal
cavity (e.g., B16 melanoma [8, 9, 11], MCA 102 sarcoma
[8], lung carcinomas [8, 12], MADB106 mammary carci-
noma [9], and lymphomas including RMA-S cells [13]).
 
Induction of Cytotoxic NK Cell Responses in the Peritoneal
Cavity Is Inhibited by Restoration of Tumor MHC Class I Ex-
pression.
 
RMA-S cells express low cell surface MHC class I
due to a defect in TAP-2, and TAP-2 transfection of RMA-S
cells restores cell surface MHC class I expression as well as
resistance to NK cell–mediated lysis (7, 30–33). Whereas
RMA-S cells induced a strong intraperitoneal NK cell re-
sponse, we found that wild-type RMA cells failed to do this
(Fig. 2, a–c). In addition, we found that TAP-2 transfec-
tion of RMA-S (RMA-S.mtp2) suppressed its ability to in-
duce a cytotoxic NK response, demonstrating that the latter
was indeed associated with the defect in antigen presenta-
tion of the challenging cells (Fig. 2, c and d).
A similar pattern of MHC class I–dependent activation
was observed with a 
 
b
 
2
 
m-deficient variant of the YAC lym-
phoma called AH-2
 
2 
 
and its 
 
b
 
2
 
m
 
2
 
 transfectant, E49.3-
 
b
 
2
 
m
(all cells of A/Sn origin; reference 34). AH-2
 
2
 
 induced a
strong cytotoxic response intraperitoneally when inoculated
into (A/Sn 
 
3
 
 CBA) F1 mice, whereas wild-type YAC and
the 
 
b
 
2
 
m transfectant E49.3-
 
b
 
2
 
m induced weaker responses,
although they were stronger than the response induced by
PBS (Table I, top). The cytotoxic PECs induced by AH-2
 
2
 
were depleted by antiasialo-GM
 
1
 
1
 
 complement, indicating
that these effectors were NK cells (Table I, top).
We next tested if intraperitoneal responsiveness to tumor
cells was dependent on the presence of functional T and B
cells by tumor inoculation of C.B-17 (H-2
 
d
 
) SCID mice
(lacking T and B cells; reference 29). We observed a mod-
erate induction of NK cell activation after intraperitoneal
inoculation of irradiated RMA cells into C.B-17 SCID, and
a slightly stronger response to RMA-S inoculation (Table I,
bottom). We hypothesized that the response to wild-type
H-2
 
b
 
 RMA cells (unlike in B6 mice of the H-2
 
b
 
 haplotype)
was due to lack of host MHC class I molecules of the tu-
mor. We therefore transfected RMA with the host MHC
class I gene H-2D
 
d
 
, and this resulted in a strong reduction
of NK cell inducing capacity (Fig. 3, b and c). The intra-
peritoneal cytotoxic activity in RMA-D
 
d
 
–inoculated mice
Figure 1. Intraperitoneal NK cell activity induced by RMA-S lym-
phoma cells. (a) Syngeneic B6 mice were inoculated with irradiated
RMA-S cells, and the PECs were tested after 1–4 d against NK-suscepti-
ble, 51Cr-labeled YAC-1 target cells in a standard cytotoxicity assay. (b)
Comparison of YAC-1 killing present in the peritoneal cavity and the
spleen 3 d after intraperitoneal inoculation with irradiated RMA-S cells.
(c) The cytotoxic PECs induced by RMA-S are asialo-GM1
1. PECs in-
duced by RMA-S injection were stained with either anti-CD8 or anti-
asialo-GM1 antiserum, subjected to complement-mediated depletion, and
subsequently tested in a 51Cr-release assay against YAC-1 target cells.132 Regulation of NK Cell Activation and Migration by MHC Class I Molecules
was similar to that in BSS-injected control mice (Fig. 3, a and
c). This early induced response is therefore dependent on sin-
gle host MHC class I alleles but independent of T and B cells.
The ability to induce an NK response in vivo in three
different systems was thus linked to insufficient MHC class I
expression in the tumor inoculate, as it was abrogated by
transfection with three different genes involved in the class I
pathway (TAP, heavy chain, or b2m), each in a cell line
where the gene restored a self-phenotype in relation to the
host. It should be noted that the NK cells induced by RMA-S
showed a typical pattern of specificity when tested as effec-
tor cells (as they killed RMA-S more efficiently than RMA),
but the MHC class I specificity was more distinct during
induction of the NK cell response (Fig. 2, b–d). This was
also observed for RMA and RMA-Dd when inoculated
into C.B-17 SCID mice; these tumor cell lines had very
different activation capability but were hardly distinguished
at all when tested as target cells (Fig. 3, b and c). It should
be noted that RMA and RMA-Dd cells have very different
abilities to escape in vivo NK cell–mediated rejection when
grafted as live tumors in vivo (42).
Induction of Strong NK Cell Activation but Not Blastogenesis
by MHC Class I–deficient Tumor Cells. Although NK cells
are characterized by a constitutive cytotoxic activity, they can
undergo cytotoxic activation and blastogenesis during early
immune responses to viruses (43). We characterized the tu-
mor cell–induced NK cell response in terms of NK cell num-
bers, phenotype, and activity of (FACS®-sorted) NK cells.
MHC class I–expressing tumors (RMA and RMA-S.Ham-2)
induced minor increases in the number of PECs, whereas
RMA-S induced a two- to threefold increase in PECs
(mean 6 SD from 15 experiments: BSS, 7.5 6 1.6 3 106;
RMA, 7.8 6 4.1 3 106; and RMA-S, 17.1 6 7.1 3 106).
FACS® analysis showed that, in addition, the PECs in-
duced by RMA-S contained an increased proportion of
NK cells, approximately threefold compared with untreated
mice (Fig. 4, b and e). Among these NK cells, we did not
find any indications of receptor-selective accumulation of
NK cells (with the 5E6 epitope binding to Ly49C interacting
with H-2Kb); the proportion of 5E61 in the total NK1.11
cells was roughly equal between control and RMA-S–inocu-
lated mice (Fig. 4, b and e). Taken together, these observa-
tions show a local accumulation of NK cells; these may be
5–10 times as numerous in the peritoneal cavity in an animal
inoculated with tumors of MHC class I–deficient phenotype.
The cytotoxic response induced by RMA-S revealed a
more drastic increase than the induction in NK1.11 cell num-
bers (Fig. 4, a, b, d, and e). This may result from the activa-
tion of individual NK 1.11 cells. To measure this, we FACS®
sorted PECs from control and tumor cell–inoculated mice.
In control mice, NK cell cytotoxic activity from both spleens
and PECs was restricted to NK1.11 cells and was compara-
tively low in PECs when compared with splenic NK1.11
cells (approximately three- to fivefold reduced on a per cell
basis; Fig. 5 a). In NK1.11 cells sorted from RMA-S–inoc-
ulated mice, we found a strong cytotoxic activation com-
Figure 2. The induction of an intra-
peritoneal NK cell response is inhibited
by restoration of tumor MHC class I
expression. Irradiated tumor cells were
inoculated intraperitoneally into synge-
neic B6 mice, and PEC cells were
tested on day 3 in a 51Cr-release assay
against the target cells indicated. Stimu-
lator cells used to inoculate syngeneic
(H-2b) C57Bl/6 mice: (a) PBS control;
(b) RMA; (c) RMA-S; and (d) RMA-
S.mtp2. Each diagram represents a
mean of at least five experiments.
Table I. MHC Class I Specificity of NK Cell Induction in 
Allogeneic (H-2d) SCID Mice and (A 3 CBA) F1 Mice
Target cell
In vivo stimulators of PECs from A 3 CBA F1*
BSS YAC AH-22 E49.3-b2m
AH-22 12, 0, 4‡ 13, 7, 1 45, 28, 13 27, 13, 3
AH-22 AH-22
1 C9§ aA-GM1 1 C9
AH-22 39, 21, 9 1, 0, 2
In vivo stimulators of C.B-17 SCID mice (H-2d)i
BSS RMA RMA-S
RMA 6, 3, 3 29, 13, 6 42, 25, 14
RMA-S 6, 6, 5 31, 19, 12 41, 28, 20
YAC-1 7, 4, 5 40, 21, 15 47, 31, 28
*H-2k/a (A 3 CBA) F1 were injected with BSS, wild-type YAC
(b2m1), mutant AH-22 (b2m2), or transfectant E49.3 (b2m1) cells.
‡Percent specific lysis in a standard 51Cr-release cytotoxicity assay. E/T
ratios tested: 100:1, 33:1, and 11:1.
§PECs induced by injection of AH-22 into (A 3 CBA) F1 mice were
depleted by complement-mediated lysis with and without pretreatment
with antiasialo-GM1 serum.
iH-2d C.B-17 SCID mice were injected with BSS, RMA, or RMA-S
(H-2b).133 Glas et al.
pared with endogenous NK1.11 cells, showing an z10-fold
increase in cytotoxicity per NK1.11 cell (Fig. 4, c and f, and
Fig. 5 b). Also, among the PECs from RMA-S–inoculated
mice, all of the cytotoxicity against YAC-1 cells was found
in the NK1.11 population. Furthermore, the cytotoxic activ-
ity of individual NK1.11 cells was dependent on the MHC
class I phenotype of the tumor, as TAP transfection of
RMA-S inhibited its activating capacity (Fig. 5 b).
NK cells induced by high serum levels of IFN-a/b dur-
ing viral infection show augmented cytotoxicity combined
with a blast-like phenotype (43). We observed a substantial
population of large cells (FSChigh) in our peritoneal exudates
induced by tumor cells. Therefore, control and RMA-S–
inoculated mouse PECs were divided into one FSChigh-
SSChigh and one FSClowSSClow population. The NK1.11 cells
were always present in the FSClowSSClow population, with
a cell size not significantly different from that of endoge-
nous NK1.11 cells, which have low cytotoxic activity (Fig.
5 a). These NK cells do not, therefore, resemble the blas-
toid NK cells induced by viral infection or by poly I:C (Fig.
5 c). Wright-Giemsa stains of PECs indicated large propor-
tions of monocytes and granulocytes in RMA-S–injected as
well as control mice, which may explain the abundant
FSChighSSChigh population of NK1.12 cells (data not shown).
The observed NK1.11 cells were TCR2, and the proportion
of CD41 and CD81 cells was relatively unchanged at z5%
of PECs (data not shown). In conclusion, the NK cell sys-
tem is mobilized in response to target cells perceived as non-
Figure 3. Regulation of NK cell activation in C.B-17
SCID mice by H-2Dd molecules. Irradiated (H-2b) tumor
cells were injected intraperitoneally into allogeneic C.B-17
(H-2d) SCID mice, and PECs were tested on day 3 in a
51Cr-release assay against target cells indicated. Stimulator
cells used to inoculate allogeneic (H-2d) C.B-17 SCID
mice: (a) BSS control; (b) RMA; and (c) RMA-Dd. The
MHC class I–specific induction of the response occurs in-
dependently of T and B cells.
Figure 4. Strong increase in cytotoxic activity of NK1.11 cells induced by intraperitoneal RMA-S inoculation. PECs from RMA-S–injected B6 (d–f)
or control mice (a–c) were analyzed by FACS® (b and e) and tested for cytotoxic activity against 51Cr-labeled YAC-1 target cells (a and d) 3 d after tumor
cell inoculation. A significant increase in NK1.11 cell numbers is induced by RMA-S. In the right panels, PECs from control (c) or RMA-S–inoculated
(f) mice were FACS® sorted into NK1.11 and NK1.12 populations and tested for cytotoxic activity against YAC-1 target cells. A strong activation of cyto-
toxic activity, as measured per NK1.11 cell, is induced by RMA-S.134 Regulation of NK Cell Activation and Migration by MHC Class I Molecules
self, resulting in up to 100-fold total augmentation of NK
cell activity locally in the peritoneal cavity. This is explained
in part by the increase in NK1.11 cell numbers and, in addi-
tion, by an z10-fold increase in activity per NK1.11 cell.
Expression of Cytokine Genes in RMA-S–activated NK1.11
Cells. NK cells can influence the activation of Th1- and
Th2-type CD41 T cells through the production of IFN-g
(27). To test whether in vivo confrontation with MHC
class I–deficient tumor cells can influence cytokine produc-
tion of PECs, we prepared cDNA from FACS®-sorted
NK1.12 and NK1.11 cells of tumor-inoculated mice. The
cDNA was amplified with cytokine-specific primers and used
in a competitive PCR assay to quantify cytokine transcripts.
b-Actin was amplified as a comparative standard (37).
NK1.11 cells from RMA-S–inoculated mice had high lev-
els of transcripts for IFN-g, whereas NK cells from mice
inoculated with TAP-2–transfected RMA-S cells contained
comparatively low levels, although they were above back-
ground (Fig. 6 a). When amplifying cDNA from NK1.12
cells in parallel, the signal was always below the level of
detection, indicating absence of IFN-g transcription in
NK1.12 cells. The induction of IFN-g transcripts correlated
with production of IFN-g protein, but this occurred only
in the presence of either RMA-S or IL-12 (Fig. 7). NK cell
recruitment in itself is therefore not sufficient for release of
the IFN-g protein. One major pathway for the induction
Figure 5. Cytotoxic activation of intraperitoneal NK1.11 cells depends on the MHC class I expression of the tumor cells. PECs from untreated B6 (a)
or tumor cell–injected B6 mice (b) were sorted by FACS® into NK1.11 and NK1.12 populations and tested for cytotoxic activity against YAC-1 target
cells. Note that the cytotoxic activity from all mice is restricted to the NK1.11 population. (a) The cytotoxic activity of endogenous NK1.11 cells from
spleen and peritoneal cavity. NK1.11 cells from the peritoneal cavity show comparatively low cytotoxic activity. (b) NK1.11 cells from RMA-S–injected
mice have a drastically induced cytotoxic activity compared with endogenous NK1.11 cells from the intraperitoneal cavity and spleen (compare to Fig.
5 a). Activation of NK1.11 cells is inhibited by TAP transfection of RMA-S. (c) Cell size of NK1.11 cells in untreated (black line) or RMA-S–injected
mice (gray line) versus poly I:C–induced NK1.11 cells (stippled line). The mean FSC for spleen lymphocytes and RBCs in this experiment was 409 and
216, respectively. No difference in cell size was observed between RMA-S–activated and endogenous NK1.11 cells.
Figure 6. Induction of IFN-g but not IL-12 in NK1.11 PECs by RMA-S cells. PECs from mice inoculated with either RMA-S or RMA-S.Ham-2
were FACS® sorted into NK1.11 and NK1.12 populations and analyzed for IFN-g (a) and IL-12 (p40) transcripts (b). Competitive PCR was used for
the quantitation of transcripts (see Materials and Methods), and the intensity of the bands is displayed as percent compared with a b-actin standard. In c,
the serum levels of IFN-a and IFN-b were measured using DELFIA (see Materials and Methods). Induction of IFN-g transcription is observed in intra-
peritoneal NK1.11 cells but not in NK1.12 cells and is dependent on tumor MHC class I expression.135 Glas et al.
of IFN-g in NK cells is mediated through IL-12 secreted
by macrophages, as observed during murine CMV infec-
tion (44, 45). However, we did not detect any transcripts
for the IL-12 p40 chain in either intraperitoneal NK1.11 or
NK1.12 cells, indicating that the induction of IFN-g tran-
scripts in NK1.11 cells does not depend on local produc-
tion of IL-12 (Fig. 6 b). Attempts to amplify IL-12 transcripts
from PECs from RMA-S–treated mice were also negative
when performed 1 d after inoculation, and the same prim-
ers amplified IL-12 transcripts from control samples (data
not shown). These data support recent data from viral in-
fection models where IL-12 is required for NK cell pro-
duction of IFN-g protein (44, 45) but also suggest that this
requirement can be partially replaced by NK cell interac-
tion with RMA-S. TNF-a is necessary for RMA-S–induced
NK cell trafficking (13), and we did detect induction of
TNF-a in NK cells from mice inoculated with RMA-S but
not with RMA-S.Ham-2 (data not shown). This may sug-
gest that NK cells themselves may mediate the attraction of
other NK cells upon recognition of tumor cells when these
tumor cells lack appropriate MHC class I expression. Fur-
thermore, we detected increased levels of IFN-a and -b in
serum from RMA-S–injected mice and lower but significant
levels in RMA-S.Ham-2–inoculated mice (Fig. 6 d). These
levels correspond approximately to those found in mice
chronically infected with LCMV but are much lower than
those detected during the acute infection, which is also con-
sistent with the lack of blastogenesis in these NK cells (46).
Discussion
Adaptive T cell–mediated immune responses against in-
tracellular antigens include two related but distinct compo-
nents: (a) a first step of recruitment/activation/expansion of
effector cells in response to cognate interaction with cells
expressing an MHC-presented antigen that the effector cell
can eliminate, and (b) generation of memory, leading to a
more rapid response upon reexposure to the same antigen.
Our study is consistent with the notion that NK cells can
also generate responses according to their specificity in the
effector cell stage corresponding to the first step listed above.
Tumor-infiltrating NK cells were recruited to the perito-
neal cavity, acquired efficient cytotoxic capacity, and tran-
scribed IFN-g provided that the challenging tumor lacked
appropriate MHC class I expression. Activation and recruit-
ment of NK cells was inhibited by restoration of MHC class
I expression in the tumor. Note also that the MHC-associ-
ated specificity was at least as distinct during activation of NK
effector cells as during effector cell lysis of target cells. This
is of particular relevance because a multitude of intracellular
parasites (e.g., MCMV) as well as mutations in tumors cause
defects in expression of MHC class I molecules (47–49). We
have not been able to demonstrate the second component
of adapted responses, a stronger memory response upon sec-
ondary tumor cell challenge (not shown).
NK cells are usually considered as part of the innate im-
mune system, which can neutralize or eliminate pathogens
or cells instantly without the need for activation. For ex-
ample, the rejection of intravenously injected NK-sensitive
tumor cells is rapid and occurs within hours (1, 31, 50).
However, it is not excluded that an activation of NK cells
occurs in response to a target and that this phase may be
crucial at certain sites where the endogenous NK cell activ-
ity is low, as in the intraperitoneal NK cells studied here.
The NK cell system shows considerable flexibility, and traf-
ficking of NK cells to organs as well as induction of cyto-
toxicity occurs in response to many different stimuli, in-
cluding tumor cell inoculation (8–22). This has been
studied with tumor cells of various origins (e.g., B16 mela-
noma [8, 9, 11], MCA 102 sarcoma [8], lung carcinomas
[8, 12], MADB106 mammary carcinoma [9], and lympho-
mas including RMA-S [13]), but the role of NK cell speci-
ficity with respect to MHC class I during the induction of
this response has not been studied. It was possible to estab-
lish this role in our study; note that activation was not only
caused by cells that had been selected and mutagenized in
vitro, but it could also be induced by MHC class I–express-
ing cells lacking a critical host MHC class I product (H-2Dd)
and inhibited by transfection of the corresponding gene.
NK cells activated by IL-2 are highly lytic against many
tumor targets and are interesting in relation to tumor im-
munotherapy. IL-2–activated NK cells can in some cases
infiltrate solid tumors and induce regression of established
lung and liver tumors (51–53). However, in many cases the
primary tumor and metastases are not efficiently infiltrated
by NK cells, leading to absence of an antitumor effect. We
describe a phenotype resulting in both efficient infiltration
and cytotoxic activation. A local decrease in MHC class I
expression (e.g., by TAP inhibition by infected cell protein
(ICP)47; reference 54) could possibly contribute to making
this therapy more efficient.
Cells deficient for MHC class I expression have increased
susceptibility for NK cells, but relatively little is known
about the ligands that normally trigger NK cells. The NKp44
and NKp46 receptors that are involved in the triggering of
human NK cells during lysis of tumor cells have recently
been characterized (55, 56). In addition, NKp46 has been
Figure 7. Secretion of IFN-g protein by RMA-S–induced PECs. Se-
cretion of IFN-g protein from untreated (unfilled bars) and RMA-S–
induced (filled bars) PECs was measured by sandwich ELISA. 2 3 105
RMA-S cells or 50 IU of IL-12 was added for 20 h before measuring se-
cretion. In the presence of medium only, the release of IFN-g was ,10
pg/ml. Secretion of IFN-g protein is induced, but this requires the pres-
ence of either RMA-S or IL-12.136 Regulation of NK Cell Activation and Migration by MHC Class I Molecules
cloned from mouse NK cells and would be one candidate
for a triggering receptor that is required for the RMA-S–
induced response (57). Many normal cell types are believed
to express activatory NK cell ligands, and self-tolerance
must then be maintained by the inhibitory signal provided
by normal MHC class I expression. Target cell ligands that
can trigger NK cell effector function range from adhesion
molecules such as intercellular adhesion molecule 2 (when
redistributed at the cell surface by Ezrin; reference 58) to
costimulatory molecules expressed by APCs (59). Whereas
deficient MHC class I expression was necessary for efficient
NK cell activation in this study, it was not sufficient. We
did not observe any NK cell activation by inoculation of ir-
radiated  b2m-deficient spleen cells, despite the fact that
these cells have a very low MHC class I expression (data
not shown). At the effector stage, NK cells can reject b2m-
deficient hematopoietic precursors in the bone marrow and
kill b2m-deficient Con A–activated T cell blasts in vitro
(60, 61). The latter may not, however, express enough ac-
tivatory ligands to activate an NK cell response. Allogeneic
cells may however possess such ligands, as rat spleen cells
from certain strains activate CD81 NK cells upon intraperi-
toneal inoculation (62). The molecular identity of the acti-
vatory ligands expressed by the cell lines tested in this paper
have not been determined, but this system may serve as a
model for the characterization of such ligands.
A number of viruses reduce MHC class I expression of in-
fected host cells. This can occur either through a general cy-
topathic effect (63) or the synthesis of proteins that specifically
interfere with processing in the MHC class I pathway (47).
Interestingly, certain cytopathic viruses such as MCMV and
murine hepatitis virus accumulate high numbers of cytotoxic
NK/LGL at the site of infection, which is not observed with
a noncytopathic LCMV strain (16). MCMV encodes genes
that prevent normal antigen processing (64), and infection
by MCMV induces local accumulation and cytotoxic acti-
vation of NK cells during early infection (17). The kinetics
of NK cell activation induced by RMA-S is similar to that
observed during viral infection, i.e., peaking after 3 d. In
this process, antiviral NK cells undergo blastogenesis (43),
and they thus accumulate at the site of viral replication as a
result of both recruitment and proliferation. Activation by
RMA-S inoculation was not associated with NK cell blas-
togenesis, supporting the conclusion that this activation
pathway is different from the IFN-a/b–dependent virus
induction pathway (45). It may also be different from the well
characterized pathway based on macrophages secreting IL-12,
leading to IFN-g secretion by NK cells (28, 44, 45). In our
system, RMA-S–induced recruitment in itself was not suffi-
cient for secretion of IFN-g protein, despite an induction of
IFN-g transcription. Secretion of IFN-g protein was induced
by RMA-S cells and more efficiently by IL-12. (Fig. 7).
Several studies of early immune responses show the im-
portance of activated IFN-g–producing NK cells for pro-
tection of the host (27, 28, 65). IFN-g produced by NK
cells can activate macrophages; it may also be important in
CD41 T cell differentiation to the Th1 subset (27, 66), and it
is therefore possible that inoculates of MHC class I–deficient
tumor cells could bias these pathways in vivo. For induction
of IFN-g transcription, we cannot exclude the possibility that
NK cells may be activated indirectly by cytokines secreted by
other cells such as macrophages, but we did not detect cyto-
kine transcripts in NK1.12 cells for IFN-g, TNF-a, or IL-12.
The RMA-S–induced peritoneal exudate contained a sig-
nificant fraction of macrophages (as seen by Wright-Giemsa
stains; data not shown), and it is possible that this mechanism
may contribute to the development of an early inflammatory
response. Indeed, NK cell–produced IFN-g is reported as a T
cell–independent pathway of macrophage activation (67).
This pathway may be controlled by cells expressing MHC
class I–specific inhibitory receptors, such as NK cells and po-
tentially other cells of the immune system (68). This mecha-
nism could operate in early responses against viruses that in-
hibit antigen processing (e.g., against HSV, expressing ICP47
that blocks TAP; reference 54). The simplest model to ex-
plain the induced NK cell response we observe is a direct in-
teraction between RMA-S and NK cells in the peritoneal
cavity. The interaction between cell surface–expressed mole-
cules on RMA-S cells and NK cells that triggers cytotoxicity
(55–57) may also trigger activation of augmented cytotoxic
capacity and production of IFN-g; other cytokines such as
TNF-a (13), which attract new NK cells to the site, may also
be secreted simultaneously. It was recently shown that NK
cell infiltration as well as tumor rejection after intraperitoneal
inoculation depends on TNF-a but not IL-12 (13). In the sit-
uations where a complete self-phenotype is detected by in-
hibitory MHC class I receptors (e.g., in TAP-2–transfected
RMA-S), all of the events above are canceled. Our data sug-
gest that cells with deficient MHC class I expression may in-
fluence the outcome of an infection, and we may speculate
about whether it is possible to use a cell with an MHC-defi-
cient phenotype as an adjuvant for NK activation as well as
for the induction of adaptive immune responses. In future
studies, it will be important to delineate the activating recep-
tor–ligand interactions underlying the type of induced NK
activity studied here, as well as to understand the cellular
mechanisms for local expansion of NK activity.
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